Commentary
Volume 10:02, 2025

Journal of Molecular Histology & Medical Physiology

ISSN: 2684-494X

Open Access

Annexin V as a Real-time Marker for Early Apoptosis Detection in Cancer Cells

Sayad Hamdi*

Department of Cancer Therapeutics, Ain Shams University, Cairo, Egypt

Introduction

Apoptosis, or programmed cell death, is a tightly regulated cellular process that plays a vital role in tissue homeostasis and development. In cancer biology, the ability to detect and monitor apoptosis in real time is crucial for evaluating the efficacy of chemotherapeutic agents and understanding tumor cell response to stress or immune-mediated cytotoxicity. Among the various biomarkers available, Annexin V has emerged as one of the most reliable and widely used probes for detecting early stages of apoptosis. Its high affinity for phosphatidylserine (PS), a phospholipid that becomes externalized on the plasma membrane during early apoptosis, makes it an ideal tool for real-time and non-invasive detection of apoptotic cells in both in vitro and in vivo settings [1].

Description

In healthy cells, PS is predominantly localized to the inner leaflet of the plasma membrane due to the action of ATP-dependent flippases. However, during the early phases of apoptosis, these flippases become inactivated and scramblases are activated, leading to the rapid translocation of PS to the outer membrane surface. This externalization of PS is one of the earliest biochemical events in apoptosis, preceding other morphological changes such as chromatin condensation, DNA fragmentation, and membrane blebbing. Annexin V, a 35-36 kDa calcium-dependent phospholipid-binding protein, exhibits high binding specificity to PS in the presence of physiological concentrations of calcium ions. The binding is reversible and does not perturb the membrane structure, enabling real-time monitoring of apoptotic cells without compromising cell integrity [2].

Annexin V is commonly conjugated with fluorophores such as fluorescein isothiocyanate (FITC), phycoerythrin (PE), or allophycocyanin (APC), allowing detection by flow cytometry, confocal microscopy, or live-cell imaging systems. When used in conjunction with propidium iodide (PI) or 7-AAD, which only permeate cells with compromised membranes, Annexin V assays can discriminate between early apoptotic (Annexin V+/PI–), late apoptotic or necrotic (Annexin V+/PI+), and viable (Annexin V–/PI–) cell populations. This dual-staining approach provides a robust and quantitative method to assess apoptosis kinetics in cancer cells exposed to cytotoxic agents, radiation, or immune effectors [3].

In oncology research, Annexin V staining has become a standard method to evaluate drug-induced apoptosis. For example, treatment of cancer cell lines with chemotherapeutic drugs such as doxorubicin, paclitaxel, or cisplatin typically results in a dose-dependent increase in Annexin V-positive cells, confirming the induction of apoptosis. Moreover, targeted therapies such as tyrosine kinase inhibitors and immune checkpoint blockers have also been studied using Annexin V-based assays to monitor therapeutic response and resistance mechanisms. Real-time imaging using Annexin V conjugates has been instrumental in elucidating the temporal sequence of apoptosis and identifying resistant subpopulations within heterogeneous tumor cell cultures.
Beyond in vitro applications, Annexin V has also been utilized in in vivo models to visualize apoptosis non-invasively. Radiolabeled Annexin V tracers, such as ^99mTc-labeled Annexin V, have been employed in nuclear medicine imaging to detect apoptotic regions within tumors using single-photon emission computed tomography (SPECT). These imaging techniques offer the potential to monitor tumor response to therapy in real time, providing a functional readout of cell death that may precede measurable changes in tumor size. Clinical studies have explored the use of Annexin V imaging to evaluate apoptosis in response to chemotherapy or radiotherapy in cancer patients, although challenges related to tracer pharmacokinetics, non-specific uptake, and imaging resolution remain [4].

Despite its many advantages, Annexin V-based detection is not without limitations. Its reliance on calcium for binding can be influenced by experimental conditions, and the interpretation of results may be confounded by PS externalization in non-apoptotic processes such as cell activation or necrosis. Additionally, the transient nature of PS exposure in early apoptosis necessitates precise timing for accurate detection. False positives may also occur in cells undergoing repair or reversible stress responses. Nonetheless, careful experimental design, appropriate controls, and combination with complementary assays (e.g., caspase activity, mitochondrial membrane potential, DNA fragmentation) can mitigate these issues and strengthen conclusions.
Recent developments in molecular imaging and bioengineering have led to the generation of more sensitive and specific Annexin V probes. Fluorescent proteins, near-infrared dyes, and nanoparticle-based platforms are being explored to enhance signal intensity, tissue penetration, and in vivo stability. Furthermore, genetically encoded Annexin V sensors have been developed to allow long-term monitoring of apoptosis in live cells, enabling longitudinal studies in cancer biology and drug development [5].

Conclusion

In conclusion, Annexin V represents a gold standard for the real-time detection of early apoptosis in cancer cells. Its ability to detect phosphatidylserine externalization with high specificity and sensitivity has made it an indispensable tool in cancer research, drug screening, and potentially clinical imaging. While technical challenges remain, ongoing advancements in probe development and imaging technologies are likely to expand its utility and precision. As our understanding of apoptosis deepens, the continued application and refinement of Annexin V-based methods will play a critical role in unraveling the complexities of cancer cell death and therapeutic response.

Acknowledgement

None.

***Address for Correspondence:** Sayad Hamdi, Department of Cancer Therapeutics, Ain Shams University, Cairo, Egypt; E-mail: hamdi.sayed@ainshams.eg*

Received: 03 March, 2025, Manuscript No. jmhmp-25-168579; **Editor Assigned:** 05 March, 2025, PreQC No. P-168579; **Reviewed:** 17 March, 2025, QC No. Q-168579; **Revised:** 24 March, 2025, Manuscript No. R-168579; **Published:** 31 March, 2025, DOI: 10.37421/2684-494X.2025.10.285

Conflict of Interest

None.

References

1. Massague, Joan and Anna C. Obenauf. "Metastatic colonization by circulating tumour cells." Nature 529 (2016): 298-306.

2. Wei, Xunbin, Dorothy A. Sipkins, Costas M. Pitsillides and John Novak, et al. "Real-time detection of circulating apoptotic cells by in vivo flow cytometry." Mol Imaging 4 (2005): 7290-2005.

3. Zeng, Wenbin, Xiaobo Wang, Pengfei Xu and Gang Liu, et al. "Molecular imaging of apoptosis: From micro to macro." Theranostics 5 (2015): 559.

4. De Toro, Julieta, Leticia Herschlik, Claudia Waldner and Claudia Mongini. "Emerging roles of exosomes in normal and pathological conditions: New insights for diagnosis and therapeutic applications." Front Immunol 6 (2015): 203.

5. Fei, Fei, Yueyao Du, Genhong Di and Jiong Wu, et al. "Are changes in circulating tumor cell (CTC) count associated with the response to neoadjuvant chemotherapy in local advanced breast cancer? A meta-analysis." Oncol Res Treat 37 (2014): 250-254.

How to cite this article: Hamdi, Sayad. "Annexin V as a Real-Time Marker for Early Apoptosis Detection in Cancer Cells." *J Mol Hist Med Phys* 10 (2025): 285.